• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Emotion - The New Brand Integrator

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-06-01-2001
Volume 0
Issue 0

Driven by the quest for innovation, the intensity of competition, and the pressure to create megabrands and megamergers, pharmaceutical executives are exploring an influential force still untapped by most marketing and communication departments-the power of emotion.

Articles in this issue
Industry Under Investigation
Covering the Bases
Emotion - The New Brand Integrator
For Love of the Game
Field of Dreams
Workshop: Access Options
Emotion - The New Brand Integrator
Rx-to-OTC: Unwanted Attention
Emotion - Biotech Renaissance Man
Biotech Renaissance Man
Relocation: Coming to America
Biotechnology: German Industry Beefs Up
Stocks: Catching the Market Blues
Gathering Light
Related Videos
Related Content
FDA Approves Amneal’s Naloxone Hydrochloride Nasal Spray as an OTC Treatment for Opioid Overdose

FDA Approves Amneal’s Naloxone Hydrochloride Nasal Spray as an OTC Treatment for Opioid Overdose

April 24th 2024
Article

Company aims to provide affordable emergency treatment from overdoses of heroin, fentanyl, and prescription opioids.

Fierce Females in the Life Science Space

Fierce Females in the Life Science Space

March 29th 2024
Podcast

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.

Image credit: peterschreiber.media | stock.adobe.com

FDA Grants Accelerated Approval to Day One’s Ojemda for Relapsed or Refractory Pediatric Low-Grade Glioma

April 24th 2024
Article

Ojemda is the first systemic therapy approved by the FDA for the treatment of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation.

Gen-Z Influence on Pharma M&A

Gen-Z Influence on Pharma M&A

March 14th 2024
Podcast

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Pharma Pulse 4/24/24: 5 Things You Should Know About Women's Health, Microsoft Makes Push Into Smaller AI Systems & more

Pharma Pulse 4/24/24: 5 Things You Should Know About Women's Health, Microsoft Makes Push Into Smaller AI Systems & more

April 24th 2024
Article

The latest news for pharma industry insiders.

Image credit: Yuriy | stock.adobe.com

FDA Approves Novartis' Lutathera for Pediatric Patients with Gastroenteropancreatic Neuroendocrine Tumors

April 23rd 2024
Article

Lutathera is the first FDA-approved treatment for younger patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.